Cargando…
A new way to estimate neurologic disease prevalence in the United States: Illustrated with MS
OBJECTIVE: Considerable gaps exist in knowledge regarding the prevalence of neurologic diseases, such as multiple sclerosis (MS), in the United States. Therefore, the MS Prevalence Working Group sought to review and evaluate alternative methods for obtaining a scientifically valid estimate of nation...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6442012/ https://www.ncbi.nlm.nih.gov/pubmed/30770422 http://dx.doi.org/10.1212/WNL.0000000000007044 |
_version_ | 1783407637336948736 |
---|---|
author | Nelson, Lorene M. Wallin, Mitchell T. Marrie, Ruth Ann Culpepper, W.J. Langer-Gould, Annette Campbell, Jon Buka, Stephen Tremlett, Helen Cutter, Gary Kaye, Wendy Wagner, Laurie Larocca, Nicholas G. |
author_facet | Nelson, Lorene M. Wallin, Mitchell T. Marrie, Ruth Ann Culpepper, W.J. Langer-Gould, Annette Campbell, Jon Buka, Stephen Tremlett, Helen Cutter, Gary Kaye, Wendy Wagner, Laurie Larocca, Nicholas G. |
author_sort | Nelson, Lorene M. |
collection | PubMed |
description | OBJECTIVE: Considerable gaps exist in knowledge regarding the prevalence of neurologic diseases, such as multiple sclerosis (MS), in the United States. Therefore, the MS Prevalence Working Group sought to review and evaluate alternative methods for obtaining a scientifically valid estimate of national MS prevalence in the current health care era. METHODS: We carried out a strengths, weaknesses, opportunities, and threats (SWOT) analysis for 3 approaches to estimate MS prevalence: population-based MS registries, national probability health surveys, and analysis of administrative health claims databases. We reviewed MS prevalence studies conducted in the United States and critically examined possible methods for estimating national MS prevalence. RESULTS: We developed a new 4-step approach for estimating MS prevalence in the United States. First, identify administrative health claim databases covering publicly and privately insured populations in the United States. Second, develop and validate a highly accurate MS case-finding algorithm that can be standardly applied in all databases. Third, apply a case definition algorithm to estimate MS prevalence in each population. Fourth, combine MS prevalence estimates into a single estimate of US prevalence, weighted according to the number of insured persons in each health insurance segment. CONCLUSIONS: By addressing methodologic challenges and proposing a new approach for measuring the prevalence of MS in the United States, we hope that our work will benefit scientists who study neurologic and other chronic conditions for which national prevalence estimates do not exist. |
format | Online Article Text |
id | pubmed-6442012 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-64420122019-04-15 A new way to estimate neurologic disease prevalence in the United States: Illustrated with MS Nelson, Lorene M. Wallin, Mitchell T. Marrie, Ruth Ann Culpepper, W.J. Langer-Gould, Annette Campbell, Jon Buka, Stephen Tremlett, Helen Cutter, Gary Kaye, Wendy Wagner, Laurie Larocca, Nicholas G. Neurology Views & Reviews OBJECTIVE: Considerable gaps exist in knowledge regarding the prevalence of neurologic diseases, such as multiple sclerosis (MS), in the United States. Therefore, the MS Prevalence Working Group sought to review and evaluate alternative methods for obtaining a scientifically valid estimate of national MS prevalence in the current health care era. METHODS: We carried out a strengths, weaknesses, opportunities, and threats (SWOT) analysis for 3 approaches to estimate MS prevalence: population-based MS registries, national probability health surveys, and analysis of administrative health claims databases. We reviewed MS prevalence studies conducted in the United States and critically examined possible methods for estimating national MS prevalence. RESULTS: We developed a new 4-step approach for estimating MS prevalence in the United States. First, identify administrative health claim databases covering publicly and privately insured populations in the United States. Second, develop and validate a highly accurate MS case-finding algorithm that can be standardly applied in all databases. Third, apply a case definition algorithm to estimate MS prevalence in each population. Fourth, combine MS prevalence estimates into a single estimate of US prevalence, weighted according to the number of insured persons in each health insurance segment. CONCLUSIONS: By addressing methodologic challenges and proposing a new approach for measuring the prevalence of MS in the United States, we hope that our work will benefit scientists who study neurologic and other chronic conditions for which national prevalence estimates do not exist. Lippincott Williams & Wilkins 2019-03-05 /pmc/articles/PMC6442012/ /pubmed/30770422 http://dx.doi.org/10.1212/WNL.0000000000007044 Text en Copyright © 2019 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. |
spellingShingle | Views & Reviews Nelson, Lorene M. Wallin, Mitchell T. Marrie, Ruth Ann Culpepper, W.J. Langer-Gould, Annette Campbell, Jon Buka, Stephen Tremlett, Helen Cutter, Gary Kaye, Wendy Wagner, Laurie Larocca, Nicholas G. A new way to estimate neurologic disease prevalence in the United States: Illustrated with MS |
title | A new way to estimate neurologic disease prevalence in the United States: Illustrated with MS |
title_full | A new way to estimate neurologic disease prevalence in the United States: Illustrated with MS |
title_fullStr | A new way to estimate neurologic disease prevalence in the United States: Illustrated with MS |
title_full_unstemmed | A new way to estimate neurologic disease prevalence in the United States: Illustrated with MS |
title_short | A new way to estimate neurologic disease prevalence in the United States: Illustrated with MS |
title_sort | new way to estimate neurologic disease prevalence in the united states: illustrated with ms |
topic | Views & Reviews |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6442012/ https://www.ncbi.nlm.nih.gov/pubmed/30770422 http://dx.doi.org/10.1212/WNL.0000000000007044 |
work_keys_str_mv | AT nelsonlorenem anewwaytoestimateneurologicdiseaseprevalenceintheunitedstatesillustratedwithms AT wallinmitchellt anewwaytoestimateneurologicdiseaseprevalenceintheunitedstatesillustratedwithms AT marrieruthann anewwaytoestimateneurologicdiseaseprevalenceintheunitedstatesillustratedwithms AT culpepperwj anewwaytoestimateneurologicdiseaseprevalenceintheunitedstatesillustratedwithms AT langergouldannette anewwaytoestimateneurologicdiseaseprevalenceintheunitedstatesillustratedwithms AT campbelljon anewwaytoestimateneurologicdiseaseprevalenceintheunitedstatesillustratedwithms AT bukastephen anewwaytoestimateneurologicdiseaseprevalenceintheunitedstatesillustratedwithms AT tremletthelen anewwaytoestimateneurologicdiseaseprevalenceintheunitedstatesillustratedwithms AT cuttergary anewwaytoestimateneurologicdiseaseprevalenceintheunitedstatesillustratedwithms AT kayewendy anewwaytoestimateneurologicdiseaseprevalenceintheunitedstatesillustratedwithms AT wagnerlaurie anewwaytoestimateneurologicdiseaseprevalenceintheunitedstatesillustratedwithms AT laroccanicholasg anewwaytoestimateneurologicdiseaseprevalenceintheunitedstatesillustratedwithms AT anewwaytoestimateneurologicdiseaseprevalenceintheunitedstatesillustratedwithms AT nelsonlorenem newwaytoestimateneurologicdiseaseprevalenceintheunitedstatesillustratedwithms AT wallinmitchellt newwaytoestimateneurologicdiseaseprevalenceintheunitedstatesillustratedwithms AT marrieruthann newwaytoestimateneurologicdiseaseprevalenceintheunitedstatesillustratedwithms AT culpepperwj newwaytoestimateneurologicdiseaseprevalenceintheunitedstatesillustratedwithms AT langergouldannette newwaytoestimateneurologicdiseaseprevalenceintheunitedstatesillustratedwithms AT campbelljon newwaytoestimateneurologicdiseaseprevalenceintheunitedstatesillustratedwithms AT bukastephen newwaytoestimateneurologicdiseaseprevalenceintheunitedstatesillustratedwithms AT tremletthelen newwaytoestimateneurologicdiseaseprevalenceintheunitedstatesillustratedwithms AT cuttergary newwaytoestimateneurologicdiseaseprevalenceintheunitedstatesillustratedwithms AT kayewendy newwaytoestimateneurologicdiseaseprevalenceintheunitedstatesillustratedwithms AT wagnerlaurie newwaytoestimateneurologicdiseaseprevalenceintheunitedstatesillustratedwithms AT laroccanicholasg newwaytoestimateneurologicdiseaseprevalenceintheunitedstatesillustratedwithms AT newwaytoestimateneurologicdiseaseprevalenceintheunitedstatesillustratedwithms |